Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.

The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observati...

Descripción completa

Detalles Bibliográficos
Autores: Pérez-Belmonte, Luis M, Sanz-Cánovas, Jaime, García de Lucas, María D, Ricci, Michele, Avilés-Bueno, Beatriz, Cobos-Palacios, Lidia, Pérez-Velasco, Miguel A, López-Sampalo, Almudena, Bernal-López, M Rosa, Jansen-Chaparro, Sergio, Miramontes-González, José P, Gómez-Huelgas, Ricardo
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/18686
Acceso en línea:http://hdl.handle.net/20.500.12105/18686
Access Level:acceso abierto
Palabra clave:health status
heart failure
obesity
semaglutide
type 2 diabetes
Diabetes Mellitus, Type 2
Glucagon-Like Peptide-1 Receptor
Glucagon-Like Peptides
Heart Failure
Humans
Obesity
Retrospective Studies
Descripción
Sumario:The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required.

Similares en LA Referencia